Laman UtamaICPT • BMV
add
Intercept Pharmaceuticals Ord Shs
Tutup sebelumnya
$329.00
Julat tahun
$329.00 - $329.00
Permodalan pasaran
794.36J USD
Nisbah P/E
-
Hasil dividen
-
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2023info | Perubahan T/T |
|---|---|---|
Hasil | 88.79J | 14.44% |
Perbelanjaan pengendalian | 86.95J | -0.41% |
Pendapatan bersih | -2.79J | -101.04% |
Margin untung bersih | -3.14 | -100.91% |
Pendapatan bagi setiap syer | 0.08 | -99.20% |
EBITDA | 1.74J | 117.27% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2023info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 322.71J | -34.25% |
Jumlah aset | 393.16J | -29.72% |
Jumlah liabiliti | 321.32J | -28.87% |
Jumlah ekuiti | 71.84J | — |
Syer tertunggak | 41.83J | — |
Harga kepada buku | 191.28 | — |
Pulangan pada aset | 0.93% | — |
Pulangan pada modal | 1.18% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2023info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -2.79J | -101.04% |
Tunai daripada operasi | 16.69J | 200.59% |
Tunai daripada pelaburan | 59.77J | -81.97% |
Tunai daripada pembiayaan | -110.00J | 57.27% |
Perubahan bersih dalam tunai | -33.70J | -163.39% |
Aliran tunai bebas | 16.70J | 211.23% |
Perihal
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
CEO
Diasaskan
2002
Tapak web
Pekerja
341
